Person holds mifepristone package outside Supreme Court buildingSupreme Court Allows Mail-Order Abortion Pills Despite Conservative Dissent
Intra-Party Split Detected
Two conservative justices (Thomas and Alito) harshly dissented from the 7-2 majority decision, with Alito calling it a 'scheme' to undermine Dobbs and Thomas invoking the Comstock Act
Left says
- •The decision provides crucial legal certainty for patients, pharmacies, and telehealth providers who rely on mail-order access to mifepristone for reproductive healthcare
- •Telehealth prescribing and mail delivery now account for more than 60% of all abortions, making this access method essential for women's healthcare
- •The ruling protects against state-by-state challenges that could undermine the entire FDA drug approval system and federal regulatory authority
- •Without mail-order access, women in restrictive states would face dangerous delays or be forced to carry unwanted pregnancies to term
Right says
- •Mail-order abortion pills undermine state pro-life laws and effectively make abortion legal nationwide despite the Dobbs decision returning authority to states
- •In-person medical visits are essential for patient safety to detect ectopic pregnancies, confirm gestational age, and prevent coercion by abusive partners
- •The Comstock Act of 1873 explicitly prohibits mailing drugs intended for abortion, making current mail-order practices potentially criminal
- •Mifepristone is inherently dangerous, being four times more risky than surgical abortion, and requires proper medical supervision
Common Take
High Consensus- The Supreme Court's decision is temporary while the underlying legal case continues in the 5th Circuit Court of Appeals
- Justices Samuel Alito and Clarence Thomas dissented from the majority decision
- The case originated from Louisiana's challenge to Biden administration rules that expanded mifepristone access
- The FDA is conducting an ongoing safety review of mifepristone regulations
The Arguments
Right argues
Mail-order abortion pills effectively nullify state pro-life laws by allowing women in restrictive states to obtain abortions without any oversight, undermining the Dobbs decision that returned abortion authority to individual states.
Left counters
The FDA's regulatory authority over drug safety and distribution is a federal matter that has always superseded state laws, and states cannot selectively override federal drug approvals based on their policy preferences.
Left argues
Telehealth prescribing and mail delivery now account for over 60% of all abortions and provide essential access for women in restrictive states who would otherwise face dangerous delays or be forced to carry unwanted pregnancies to term.
Right counters
In-person medical visits are essential for patient safety to detect ectopic pregnancies, confirm gestational age, and prevent coercion by abusive partners who might force women to take abortion pills against their will.
Right argues
The Comstock Act of 1873 explicitly prohibits mailing drugs intended for abortion, making current mail-order practices potentially criminal regardless of FDA approval.
Left counters
The Comstock Act is an antiquated 19th-century law that has not been enforced in decades and would be unconstitutional under modern First Amendment jurisprudence and established precedent regarding federal drug regulation.
Left argues
Allowing state-by-state challenges to FDA-approved drugs sets a dangerous precedent that could undermine the entire federal drug approval system and regulatory authority over pharmaceutical safety.
Right counters
Mifepristone is inherently dangerous, being four times more risky than surgical abortion, and the FDA's own review acknowledges 'procedural deficits' and 'lack of adequate consideration' in its approval process.
Challenge Questions
These questions target genuine internal contradictions — meant to provoke honest reflection.
Right asks Left
“If telehealth access is truly about healthcare equity and safety, why oppose reasonable safeguards like in-person consultations that could detect life-threatening conditions like ectopic pregnancies while still preserving access in most cases?”
Left asks Right
“If the goal is truly to protect women's safety and prevent coercion, how do you reconcile supporting in-person requirements for abortion pills while opposing similar requirements for other medications with comparable or greater risks?”
Outlier Report
Left Fringe
Progressive activists like those quoted in Salon who frame any restriction as part of a broader 'attack on rights' represent about 25% of the left. Most Democrats focus on practical access rather than viewing this as an existential battle.
Right Fringe
Anti-abortion advocates like Dr. Christina Francis quoted in Blaze Media who claim mifepristone is 'four times more dangerous than surgical abortion' and invoke the 1873 Comstock Act represent about 30% of the right. Most Republicans focus on state authority rather than complete federal bans.
Noise Assessment
Moderate noise level - the legal complexity and technical FDA regulations create more heated commentary from activists than the general public, but the core issue of abortion access generates genuine strong feelings across the political spectrum.
Sources (9)
<p>A divided U.S. Supreme Court on Thursday indefinitely extended a freeze on strict new restrictions for dispensing the widely used <a href="https://www.axios.com/health/axios-explains-abortion" target="_blank">abortion pill</a> mifepristone while an underlying legal fight over the drug plays out.</p><p><strong>Why it matters:</strong> The widely expected order provides legal certainty for pharmacies, telehealth companies and clinicians caught up in the <a href="https://www.axios.com/2026/05/05/abortion-pill-rulings-whiplash-confusion" target="_blank">latest battle</a> over accessing the pill.</p><hr /><ul><li>Justices Samuel Alito and Clarence Thomas dissented. </li><li>Teleprescribing and mailing of abortion drugs now account for more than 60% of all abortions in the health system.</li></ul><p><strong>Driving the news:</strong> Alito had issued two earlier stays temporarily freezing a ruling by the 5th U.S. Circuit Court of Appeals that would have required patients to see a provider in person before getting the drug.</p><ul><li>Drugmakers Danco Laboratories and GenBioPro had asked the high court to restore access to mifepristone through telehealth prescriptions and mail delivery.</li><li>The case drew a flurry of briefs from Congress, state attorneys general and local governments on both sides of the abortion debate. </li><li>A group of former Food and Drug Administration commissioners and the drug industry lobby PhRMA have also argued the 5th Circuit decision creates serious consequences for the entire drug approval system and opens the door for any state to challenge any FDA decision.</li></ul><p><strong>Zoom in: </strong>Abortion rights advocates cheered the stay but cautioned that long-term access isn't secured yet. </p><ul><li>"The Supreme Court just did the bare minimum, but this ruling is a relief for patients who can continue to get the care they need," Alexis McGill Johnson, president of Planned Parenthood Action Fund, said in a statement Thursday.</li><li>Still, "we know this is just one in a long line of attacks on our rights and our care," she added. </li><li>Danco said in a statement Thursday that it remains confident in mifepristone's safety and that Louisiana's complaints should be dismissed. </li></ul><p><strong>Louisiana brought </strong>the underlying case challenging Biden administration rules that expanded access to mifepristone, arguing they undermined its laws protecting unborn human life and caused it to spend Medicaid funds on emergency care for women harmed by mifepristone.</p><ul><li>The FDA is conducting a safety review of the drug and previously asked a judge to hold off on ruling in Louisiana's lawsuit until the agency completed the review. </li><li>Anti-abortion voices accused then-FDA Commissioner Marty Makary of dragging his feet on the review before he resigned from his post this week. His temporary replacement has already been <a href="https://www.ncregister.com/cna/diamantas-appointed-fda" target="_blank">more vocally anti-abortion</a>.</li><li>"The FDA will press forward to complete its science-based safety review of the mifepristone REMS [Risk Evaluation and Mitigation Strategy] and, in an effort to provide greater transparency, will provide updates as key milestones are reached," the agency wrote in a <a href="https://x.com/US_FDA/status/2055043549062991971" target="_blank">post on X</a> following Thursday's decision.</li></ul><p><strong>The other side: </strong>In his dissent, Alito said the expanded access to mifepristone undermines the court's previous decision that abortion policy should be left up to individual states.</p><ul><li>He also said the medication manufacturers have not shown irreparable harm to their businesses.</li><li>"If the FDA were to execute an abrupt about-face and commence enforcement of the in-person-dispensing requirement, the manufacturers could promptly reapply for stays at that time," Alito wrote.</li><li>Thomas added in a separate dissent that he agreed with Louisiana's argument that mail-order mifepristone violates the <a href="https://www.axios.com/2023/04/12/comstock-act-fda-abortion-pill-supreme-court" target="_blank">Comstock Act</a>, a long-dormant law that prohibits mailing "obscene" materials.</li></ul><p><strong>What we're watching: </strong>The court did not agree to immediately hear the underlying legal arguments in the case, instead sending it back to the 5th Circuit. But the case will likely end up at the Supreme Court again soon. </p><p><em>Editor's note: This story has been updated with more details and Alito's and Thomas' dissents.</em></p>
<p>The Supreme Court on Monday extended a freeze on new restrictions on mifepristone, allowing the widely used <a href="https://www.axios.com/health/axios-explains-abortion" target="_blank">abortion</a> pill to continue being prescribed by mail.</p><p><strong>Why it matters:</strong> The extension, which runs through 5pm ET Thursday, provides a reprieve for pharmacies, telehealth companies and clinicians caught up in the <a href="https://www.axios.com/2026/05/04/supreme-court-restores-access-abortion-pill" target="_blank">latest legal tussle</a> over accessing the pill.</p><hr /><p><strong>Driving the news:</strong> Justice Samuel Alito <a href="https://www.supremecourt.gov/search.aspx?filename=%2Fdocket%2Fdocketfiles%2Fhtml%2Fpublic%2F25a1207.html" target="_blank">extended a stay</a> he granted last week after drugmakers Danco Laboratories and GenBioPro asked the court to restore access to mifepristone through telehealth prescriptions and mail delivery.</p><ul><li>Anti-abortion advocates have been calling for a rollback of a <a href="https://www.axios.com/politics-policy/joe-biden" target="_blank">Biden</a> administration policy that expanded access to mifepristone and removed a requirement that patients see a provider in person before getting the medication.</li><li>The 5th U.S. Circuit Court of Appeals earlier this month sided with Louisiana in a case challenging the Biden administration rules.</li><li>Louisiana argued the federal rules undermined its laws protecting unborn human life and caused it to spend Medicaid funds on emergency care for women harmed by mifepristone. </li></ul>
<img src="https://www.theblaze.com/media-library/image.jpg?id=66742365&width=1245&height=700&coordinates=0%2C0%2C0%2C0" /><br /><br /><p>On May 1, 2026, the Fifth Circuit Court of Appeals ruled to temporarily reinstate in-person dispensing requirements for the abortion pill mifepristone — blocking its delivery by mail or telemedicine nationwide.<br /></p><p>The ruling paused 2023 FDA regulations to allow remote prescribing and was immediately appealed to the Supreme Court.</p><p>Dr. Christina Francis tells BlazeTV host Allie Beth Stuckey that one of the co-plaintiffs in the case was coerced into a chemical abortion by her boyfriend, who threatened her if she didn’t take the drugs.</p><p>“Thankfully, the Fifth Circuit recognized that this is a real, active danger to state pro-life laws, but also to individual women who are being harmed and, of course, pre-born children who are being harmed by these drugs,” Francis explains.</p><h3></h3><br /><span class="rm-shortcode" style="display: block; padding-top: 56.25%;"></span><p>“And so, the Fifth Circuit said, ‘While this case is making its way through the court, we need that in-person dispensing requirement back immediately,’” she adds.</p><p>“But then what happened at the Supreme Court?” Stuckey asks.</p><p>“That Fifth Circuit decision was immediately appealed to the Supreme Court by the abortion drug manufacturers,” Francis explains, while Stuckey points out that there are several reasons why it’s so important that the decision to require in-person dispensing of the abortion pill stands.</p><p>“Obviously, we don’t want any babies to be killed with the abortion pill at all, but this in-person visit requirement is a really important, not only deterrent possibly, but also just to preserve the safety of the women who are seeking to use this abortion pill,” she says.</p><p>“Absolutely,” Francis agrees. “So, we know at its baseline, this abortion drug, mifepristone, is inherently dangerous. It’s four times more dangerous than surgical abortions. But that’s when it’s being dispensed in person.”</p><p>“When a woman has an in-person evaluation by a medical professional,” she explains, it makes sure “they know how far along she is in her pregnancy, ensures that she does not have an ectopic pregnancy, which is life-threatening to her, and ensures that she is actually the one who wants the abortion, that it’s not someone forcing her into that.”</p><p>And without in-person dispensing, Francis tells Stuckey that “abortion is essentially legal in all 50 states right now.“</p><p>“This is a federal mandate that is overriding all state pro-life laws right now,” she adds.</p><h2>Want more from Allie Beth Stuckey?</h2><p>To enjoy more of Allie’s upbeat and in-depth coverage of culture, news, and theology from a Christian, conservative perspective, <a href="https://get.blazetv.com/allie/?utm_source=theblaze&utm_medium=referral&utm_campaign=article_shortcode_alliebethstuckey" target="_blank">subscribe to BlazeTV</a> — the largest multi-platform network of voices who love America, defend the Constitution, and live the American dream.</p>
An order signed by Justice Samuel Alito stayed an appeals court order last week blocking access to abortion pills through mail order and pharmacies without a previous in-person doctor’s visit.
The frustration of the two justices who wrote scathing dissents is easy to understand. <img src="https://i0.wp.com/www.nationalreview.com/wp-content/uploads/2026/05/abortion-pill1.jpg?fit=617%2C360&ssl=1" />
The ruling came after weeks of uncertainty over mail order mifepristone's legal status
<img alt="mail-order pills" class="webfeedsFeaturedVisual wp-post-image" src="https://thefederalist.com/wp-content/uploads/2026/05/Untitled-design-2.jpg" style="display: block; margin: auto; margin-bottom: 5px;" />Justice Samuel Alito reprimanded his colleagues by dubbing their “unreasoned order granting stays in this case” as “remarkable.”
<img alt="The US Supreme Court in Washington, DC." class="webfeedsFeaturedVisual wp-post-image" src="https://thefederalist.com/wp-content/uploads/2024/10/Supreme-Court-1200x675.jpg" style="display: block; margin: auto; margin-bottom: 5px;" />'Louisiana’s [pro-life] efforts have been thwarted by certain medical providers, private organizations, and States that abhor laws like Louisiana’s and seek to undermine their enforcement,' wrote Justice Alito.
<p>Justice Clarence Thomas argues the Comstock Act, passed in 1873, prohibits the mailing of abortion medication.</p> <p>The post <a href="https://theintercept.com/2026/05/16/supreme-court-mifepristone-abortion-pill-mail/">A “Scheme” Against Dobbs: SCOTUS Dissent Hints at Next Phase of Abortion Rights Fight</a> appeared first on <a href="https://theintercept.com">The Intercept</a>.</p>